Trial Profile

An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination With Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Dec 2024 Trial design presented at the 66th American Society of Hematology Annual Meeting and Exposition.
16 Oct 2024 According to BeiGene media release, Trial-in-progress data will be presented in an oral presentation at at the 12th International Workshop on Waldenstrom Macroglobulinemia (IWWM) Oct. 17-19 in Prague, Czech Republic.
25 Jun 2024 Arms increased from 3 to 4. New experimental cohort (cohort 4: Participants with previously untreated WM will receive sonrotoclax and zanubrutinib combination therapy with fixed duration) added newly.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com